less than 60kg, 600mg/day p.o., 24weeks, 60kg - 80kg, 800mg/day p.o., 24 weeks, more than 80kg, 1000mg/day p.o., 24weeks
Sponsors
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
Conditions
Chronic hepatitis C
Unknown Phase
Non-inferiority study of telaprevir dose reduction regimen on telaprevir with pegylated interferon and ribavirin therapy for treatment-naive patients with chronic hepatitis C genotype 1; prospective randomized controlled, multicenter trial
Active, not recruitingJPRN-UMIN000007313
Start: 2012-03-01Target: 280Updated: 2026-06-29
Non-inferiority study of telaprevir dose reduction regimen on telaprevir with pegylated interferon and ribavirin therapy for treatment-experienced patients with chronic hepatitis C genotype 1; prospective randomized controlled, multicenter trial
Active, not recruitingJPRN-UMIN000007330
Start: 2012-03-01Target: 280Updated: 2026-06-29